<DOC>
	<DOCNO>NCT01085058</DOCNO>
	<brief_summary>This investigator initiate trial prospective , open , single-arm , diagnostic-prognostic study . Patients receive high-dose therapy autologous stem cell transplantation treatment lymphoproliferative disease include study . After completion high-dose therapy ( day -2 respect stem cell transplantation ) first blood sample A cytocapacity test determination leukocytes neutrophil take even day -1 . Directly thereafter study medication administer . The second blood sample B cytocapacity test determination leukocytes neutrophil take morning day 0 , 12-14 hour administration study medication . Thereafter stem cell re-infusion perform . The primary objective study show cytocapacity test lenograstim useful predictive tool respect risk post-transplant complication prolong myelosuppression , typically occur high-dose chemotherapy . The primary variable : - rate patient document infection - time platelet engraftment</brief_summary>
	<brief_title>Predictive Value `` Cytocapacity Test '' Patients With Lymphoproliferative Diseases High-dose Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Presence histologically proven lymphoproliferative disease specify Hodgkin 's disease , nonHodgkin 's lymphoma ( NHL ) multiple myeloma Indication highdose therapy autologous peripheral blood stem cell transplantation Availability sufficient amount blood stem cell ( CD34+ cell &gt; = 2.0 x 106/kg ) Age 18 70 year Highdose therapy one follow highdose regime : Melphalan 140 mg/m2 200 mg/m2 , BEAM , BEAC , BUCY CBV ( last permit accord amendment 2 , see Section 9.8.1 ) Patient 's write consent participation trial Previous highdose therapy blood stem cell transplantation except melphalan 140 mg/m2 200 mg/m2 patient multiple myeloma participate cytocapacity test previously ( accord amendment 2 , see Section 9.8.1 ) . Known intolerance lenograstim Outpatient therapy follow highdose therapy blood stem cell transplantation Myocardial infarction &lt; 6 month prior inclusion study Cardiac arrhythmias Lown IV b Clinically manifest cardiac insufficiency ( &gt; NYHA II ) Renal insufficiency serum creatinine &gt; 2 mg % Hepatic disease elevate level transaminase bilirubin great 3fold normal Severe infection ( HIV , Hepatitis B/C ) Severe psychiatric disease Noncurative treatment malignoma within past 5 year Pregnant woman woman breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Lymphoproliferative disease ( Hodgkin 's disease , non-Hodgkin 's lymphoma , multiple myeloma ) high-dose therapy</keyword>
</DOC>